A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

NCT07725939 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

402

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease With Chronic Bronchitis

Interventions

BIOLOGICAL: Galvokimig
BIOLOGICAL: Placebo

Sponsor

UCB Biopharma SRL